Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2014

Open Access 01-12-2014 | Review

Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review

Authors: Olivier Bonnot, Hans Hermann Klünemann, Frederic Sedel, Sylvie Tordjman, David Cohen, Mark Walterfang

Published in: Orphanet Journal of Rare Diseases | Issue 1/2014

Login to get access

Abstract

Objective

It is important for psychiatrists to be aware of certain inborn errors of metabolism (IEMs) as these rare disorders can present as psychosis, and because definitive treatments may be available for treating the underlying metabolic cause. A systematic review was conducted to examine IEMs that often present with schizophrenia-like symptoms.

Data sources

Published literature on MEDLINE was assessed regarding diseases of homocysteine metabolism (DHM; cystathionine beta-synthase deficiency [CbS-D] and homocysteinemia due to methyltetrahydrofolate reductase deficiency [MTHFR-D]), urea cycle disorders (UCD), acute porphyria (POR), Wilson disease (WD), cerebrotendinous-xanthomatosis (CTX) and Niemann-Pick disease type C (NP-C).

Study selection

Case reports, case series or reviews with original data regarding psychiatric manifestations and cognitive impairment published between January 1967 and June 2012 were included based on a standardized four-step selection process.

Data extraction

All selected articles were evaluated for descriptions of psychiatric signs (type, severity, natural history and treatment) in addition to key disease features.

Results

A total of 611 records were identified. Information from CbS-D (n = 2), MTHFR-D (n = 3), UCD (n = 8), POR (n = 12), WD (n = 11), CTX (n = 14) and NP-C publications (n = 9) were evaluated. Six non-systematic literature review publications were also included. In general, published reports did not provide explicit descriptions of psychiatric symptoms. The literature search findings are presented with a didactic perspective, showing key features for each disease and psychiatric signs that should trigger psychiatrists to suspect that psychotic symptoms may be secondary to an IEM.

Conclusion

IEMs with a psychiatric presentation and a lack of, or sub-clinical, neurological signs are rare, but should be considered in patients with atypical psychiatric symptoms.
Appendix
Available only for authorised users
Literature
1.
Price G, Ron MA: Schizophrenia and schizophrenia-like psychosis. Neurology and Clinical Neuroscience. Edited by: Schapira AHV. 2003, St Louis: Elsevier-Mosby, 223-233. 1
2.
Davison K, Bagley CR: Schizophrenia-like psychoses associated with organic cerebral disorders: a review. Psychiatr Dev. 1983, 1 (1): 1-33.PubMed
3.
Johnstone EC, Macmillan JF, Crow TJ: The occurrence of organic disease of possible or probable aetiological significance in a population of 268 cases of first episode schizophrenia. Psychol Med. 1987, 17 (2): 371-379.PubMed
4.
Lauterbach MD, Stanislawski-Zygaj AL, Benjamin S: The differential diagnosis of childhood and young adult onset disorders that include psychosis. J Neuropsychiatry Clin Neurosci. 2008, 20 (4): 409-418.PubMed
5.
Saudubray JM: Neurometabolic disorders. J Inherit Metab Dis. 2009, 32 (5): 595-596.PubMed
6.
Applegarth DA, Toone JR, Lowry RB: Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics. 2000, 105 (1): e10-PubMed
7.
Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D: Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007, 30 (5): 631-641.PubMed
8.
Wilson WP, Nashold BS: Psychiatric considerations of certain neurological diseases treated neurosurgically. Int Psychiatry Clin. 1967, 4 (2): 189-204.PubMed
9.
Bonnot O, Cohen D: [Psychiatric and cognitive signs associated with inborn errors of metabolism]. Rev Neurol. 2011, 167 (12): 881-885.PubMed
10.
Estrov Y, Scaglia F, Bodamer OA: Psychiatric symptoms of inherited metabolic disease. J Inherit Metab Dis. 2000, 23 (1): 2-6.PubMed
11.
Martins AM: Inborn errors of metabolism: a clinical overview. Sao Paulo medical journal =. Rev Paul Med. 1999, 117 (6): 251-265.
12.
Trifiletti RR, Packard AM: Metabolic disorders presenting with behavioral symptoms in the school-aged child. Child Adolesc Psychiatr Clin N Am. 1999, 8 (4): 791-806.PubMed
13.
14.
15.
Abbott MH, Folstein SE, Abbey H, Pyeritz RE: Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. Am J Med Genet. 1987, 26 (4): 959-969.PubMed
16.
Li SC, Stewart PM: Homocystinuria and psychiatric disorder: a case report. Pathology. 1999, 31 (3): 221-224.PubMed
17.
Baric I: Inherited disorders in the conversion of methionine to homocysteine. J Inherit Metab Dis. 2009, 32 (4): 459-471.PubMed
18.
Mattson MP, Shea TB: Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003, 26 (3): 137-146.PubMed
19.
Roze E, Gervais D, Demeret S, Ogier de Baulny H, Zittoun J, Benoist JF, Said G, Pierrot-Deseilligny C, Bolgert F: Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch Neurol. 2003, 60 (10): 1457-1462.PubMed
20.
Gilbody S, Lewis S, Lightfoot T: Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007, 165 (1): 1-13.PubMed
21.
Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J: Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res. 2008, 98 (1–3): 47-54.PubMedPubMedCentral
22.
Frankenburg FR: The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatry. 2007, 15 (4): 146-160.PubMed
23.
Friso S, Choi SW: Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005, 6 (1): 37-46.PubMed
24.
Sharma RP: Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr Res. 2005, 72 (2–3): 79-90.PubMed
25.
Regland B: Schizophrenia and single-carbon metabolism. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005, 29 (7): 1124-1132.
26.
O'Donnell C, Stephens T: The significance of homocysteine levels in schizophrenia. Am J Psychiatry. 2005, 162 (7): 1387-1388. author reply 1388–1389PubMed
27.
Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M: Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2006, 11 (2): 143-149.PubMed
28.
Haberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Lindner M, Rubio V, Dionisi-Vici C: Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012, 7: 32-PubMedPubMedCentral
29.
Singh RH: Nutritional management of patients with urea cycle disorders. J Inherit Metab Dis. 2007, 30 (6): 880-887.PubMed
30.
Smith W, Kishnani PS, Lee B, Singh RH, Rhead WJ, Sniderman King L, Smith M, Summar M: Urea cycle disorders: clinical presentation outside the newborn period. Crit Care Clin. 2005, 21 (4 Suppl): S9-17.PubMed
31.
Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW: Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. N Engl J Med. 1990, 322 (23): 1652-1655.PubMed
32.
Enns GM, O'Brien WE, Kobayashi K, Shinzawa H, Pellegrino JE: Postpartum “psychosis” in mild argininosuccinate synthetase deficiency. Obstet Gynecol. 2005, 105 (5 Pt 2): 1244-1246.PubMed
33.
Bachmann C: Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr. 2003, 162 (6): 410-416.PubMed
34.
Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML: Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res. 2009, 66 (1): 96-101.PubMedPubMedCentral
35.
Legras A, Labarthe F, Maillot F, Garrigue MA, Kouatchet A, Ogier de Baulny H: Late diagnosis of ornithine transcarbamylase defect in three related female patients: polymorphic presentations. Crit Care Med. 2002, 30 (1): 241-244.PubMed
36.
Myers JH, Shook JE: Vomiting, ataxia, and altered mental status in an adolescent: late-onset ornithine transcarbamylase deficiency. Am J Emerg Med. 1996, 14 (6): 553-557.PubMed
37.
Panlaqui OM, Tran K, Johns A, McGill J, White H: Acute hyperammonemic encephalopathy in adult onset ornithine transcarbamylase deficiency. Intensive Care Med. 2008, 34 (10): 1922-1924.PubMed
38.
Thurlow VR, Asafu-Adjaye M, Agalou S, Rahman Y: Fatal ammonia toxicity in an adult due to an undiagnosed urea cycle defect: under-recognition of ornithine transcarbamylase deficiency. Ann Clin Biochem. 2010, 47 (Pt 3): 279-281.PubMed
39.
40.
Cashman MD: Psychiatric aspects of acute porphyria. Lancet. 1961, 1 (7168): 115-116.PubMed
41.
Tishler PV, Woodward B, O'Connor J, Holbrook DA, Seidman LJ, Hallett M, Knighton DJ: High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry. 1985, 142 (12): 1430-1436.PubMed
42.
Boon FF, Ellis C: Acute intermittent porphyria in a children’s psychiatric hospital. J Am Acad Child Adolesc Psychiatry. 1989, 28 (4): 606-609.PubMed
43.
Santosh PJ, Malhotra S: Varied psychiatric manifestations of acute intermittent porphyria. Biol Psychiatry. 1994, 36 (11): 744-747.PubMed
44.
Goldberg A: Acute intermittent porphyria: a study of 50 cases. Q J Med. 1959, 28 (110): 183-209.PubMed
45.
Stein JA, Tschudy DP: Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine. 1970, 49 (1): 1-16.PubMed
46.
Bonkowsky HL, Schady W: Neurologic manifestations of acute porphyria. Semin Liver Dis. 1982, 2 (2): 108-124.PubMed
47.
Mandoki MW, Sumner GS: Psychiatric manifestations of hereditary coproporphyria in a child. J Nerv Ment Dis. 1994, 182 (2): 117-118.PubMed
48.
Brodie MJ, Thompson GG, Moore MR, Beattie AD, Goldberg A: Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med. 1977, 46 (182): 229-241.PubMed
49.
Crimlisk HL: The little imitator–porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry. 1997, 62 (4): 319-328.PubMedPubMedCentral
50.
Kuhnel A, Gross U, Doss MO: Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem. 2000, 33 (6): 465-473.PubMed
51.
Gross U, Puy H, Meissauer U, Lamoril J, Deybach JC, Doss M, Nordmann Y, Doss MO: A molecular, enzymatic and clinical study in a family with hereditary coproporphyria. J Inherit Metab Dis. 2002, 25 (4): 279-286.PubMed
52.
Pfeffer RF: Wilson’s disease. Semin Neurol. 2007, 27 (2): 123-132.
53.
Williams J, Walshe J: Wilson’s disease: an analysis of the cranial computerized tomographic appearances found in 60 patients and the changes in response to treatment with chelating agents. Brain. 1981, 104: 735-752.PubMed
54.
Roh JK, Lee TG, Wie BA, Lee SB, Park SH, Chang KH: Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson’s disease. Neurology. 1994, 44 (6): 1064-1068.PubMed
55.
Hawkins RA, Mazziotta JC, Phelps ME: Wilson’s disease studied with FDG and positron emission tomography. Neurology. 1987, 37 (11): 1707-1711.PubMed
56.
Barthel W, Markwardt F: Aggregation of blood platelets by adrenaline and its uptake. Biochem Pharmacol. 1975, 24 (20): 1903-1904.PubMed
57.
Dening TR: The neuropsychiatry of Wilson’s disease: a review. Int J Psychiatry Med. 1991, 21 (2): 135-148.PubMed
58.
Schwartz M, Fuchs S, Polak H, Sharf B: [Psychiatric manifestations in Wilson’s disease]. Harefuah. 1993, 124 (2): 75-77. 120PubMed
59.
Rathbun JK: Neuropsychological aspects of Wilson’s disease. Int J Neurosci. 1996, 85 (3–4): 221-229.PubMed
60.
Dening TR, Berrios GE: Wilson’s disease. Psychiatric symptoms in 195 cases. Arch Gen Psychiatry. 1989, 46 (12): 1126-1134.PubMed
61.
Dening TR: Psychiatric aspects of Wilson’s disease. Br J Psychiatry. 1985, 147: 677-682.PubMed
62.
Coscia L, Causa P, Giuliani E, Nunziata A: Pharmacological properties of new neuroleptic compounds. Arzneimittelforschung. 1975, 25 (9): 1436-1442.PubMed
63.
Akil M, Brewer GJ: Psychiatric and behavioral abnormalities in Wilson’s disease. Adv Neurol. 1995, 65: 171-178.PubMed
64.
Akil M, Schwartz JA, Dutchak D, Yuzbasiyan-Gurkan V, Brewer GJ: The psychiatric presentations of Wilson’s disease. J Neuropsychiatry Clin Neurosci. 1991, 3 (4): 377-382.PubMed
65.
Dening TR, Berrios GE: Wilson’s disease: a longitudinal study of psychiatric symptoms. Biol Psychiatry. 1990, 28 (3): 255-265.PubMed
66.
Medalia A, Scheinberg IH: Psychopathology in patients with Wilson’s disease. Am J Psychiatry. 1989, 146 (5): 662-664.PubMed
67.
Srinivas K, Sinha S, Taly AB, Prashanth LK, Arunodaya GR, Janardhana Reddy YC, Khanna S: Dominant psychiatric manifestations in Wilson’s disease: a diagnostic and therapeutic challenge!. J Neurol Sci. 2008, 266 (1–2): 104-108.PubMed
68.
Renaud B, Buda M, Lewis BD, Pujol JF: Effects of 5,6-dihydroxytryptamine on tyrosine-hydroxylase activity in central catecholaminergic neurons of the rat. Biochem Pharmacol. 1975, 24 (18): 1739-1742.PubMed
69.
Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR: Wilson disease: description of 282 patients evaluated over 3 decades. Medicine. 2007, 86 (2): 112-121.PubMed
70.
Sagawa M, Takao M, Nogawa S, Mizuno M, Murata M, Amano T, Koto A: [Wilson’s disease associated with olfactory paranoid syndrome and idiopathic thrombocytopenic purpura]. No to shinkei = Brain and nerve. 2003, 55 (10): 899-902.PubMed
71.
Wichowicz H, Cubala W, Slawek J: Wilson’s disease asociated with delusional disorder. Psychiatry Clin Neurosci. 2006, 60: 758-760.PubMed
72.
Spyridi S, Diakogiannis I, Michaelides M, Sokolaki S, Iacovides A, Kaprinis G: Delusional disorder and alcohol abuse in a patient with Wilson’s disease. Gen Hosp Psychiatry. 2008, 30 (6): 585-586.PubMed
73.
Stiller P, Kassubek J, Schonfeldt-Leucona C, Connemann B: Wilson’s disease in psychiatric patients. Psychiatry Clin Neurosci. 2008, 56: 649-
74.
Medalia A, Isaacs-Glaberman K, Scheinberg IH: Neuropsychological impairment in Wilson’s disease. Arch Neurol. 1988, 45 (5): 502-504.PubMed
75.
Isaacs-Glaberman K, Medalia A, Scheinberg IH: Verbal recall and recognition abilities in patients with Wilson’s disease. Cortex. 1989, 25 (3): 353-361.PubMed
76.
Ardenne M, Reitnauer PG: Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities. Arzneimittelforschung. 1975, 25 (9): 1369-1379.PubMed
77.
Kroger H, Donner I, Skiello G: Influence of a new virostatic compound on the induction of enzymes in rat liver. Arzneimittelforschung. 1975, 25 (9): 1426-1429.PubMed
78.
Smith RJ, Bryant RG: Metal substitutions incarbonic anhydrase: a halide ion probe study. Biochem Biophys Res Commun. 1975, 66 (4): 1281-1286.PubMed
79.
Walter G, Lyndon B: Depression in hepatolenticular degeneration (Wilson’s disease). Aust N Z J Psychiatry. 1997, 31 (6): 880-882.PubMed
80.
Machado A, Deguti M, Caixeta L, Spitz M, Lucato L, Barbosa E: Mania as the first manifestation of Wilson’s disease. Bipolar Disord. 2008, 10: 447-450.PubMed
81.
Tu J: The inadvisability of neuroleptic medication in Wilson’s disease. Biol Psychiatry. 1981, 16 (10): 963-968.PubMed
82.
Hoogenraad T: Wilson’s Disease. 1996, London: Saunders
83.
Chroni E, Lekka NP, Tsibri E, Economou A, Paschalis C: Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson’s disease. J Neuropsychiatry Clin Neurosci. 2001, 13 (4): 531-532.PubMed
84.
Varghese ST, Narayanan D, Dinesh D: Mania in a patient with Wilson’s disease awaiting liver transplant. J Neuropsychiatry Clin Neurosci. 2008, 20 (4): 501-502.PubMed
85.
Krim E, Barroso B: [Psychiatric disorders treated with clozapine in a patient with Wilson’s disease]. Presse Med. 2001, 30 (15): 738-PubMed
86.
Kulaksizoglu IB, Polat A: Quetiapine for mania with Wilson’s disease. Psychosomatics. 2003, 44 (5): 438-439.PubMed
87.
Longanathan S, Nayak R, Sinha S, Taly A, Math S, Varghese M: Treating mania in Wilson’s disease with lithium. J Neuropsychiatry Clin Neurosci. 2008, 20: 487-489.
88.
Rodrigues AC, Dalgalarrondo P, Banzato CE: Successful ECT in a patient with a psychiatric presentation of Wilson’s disease. J ECT. 2004, 20 (1): 55-PubMed
89.
Shah N, Kumar D: Wilson’s disease, psychosis, and ECT. Convuls Ther. 1997, 13 (4): 278-279.PubMed
90.
Negro P, Louza Neto M: Results of ECT for a case of depression in Wilson disease. J Neuropsychiatry Clin Neurosci. 1995, 7: 384-
91.
Sechi G, Antonio Cocco G, Errigo A, Deiana L, Rosati G, Agnetti V, Stephen Paulus K, Mario Pes G: Three sisters with very-late-onset major depression and parkinsonism. Parkinsonism Relat Disord. 2007, 13 (2): 122-125.PubMed
92.
Chan K, Cheung R, Au-Yeung K, Mak W, Cheng T, Ho S: Wilson’s disease with depression and parkinsonism. J Clin Neurosci. 2004, 12: 303-305.
93.
Keller R, Torta R, Lagget M, Crasto S, Bergamasco B: Psychiatric symptoms as late onset of Wilson’s disease: neuroradiological findings, clinical features and treatment. Ital J Neurol Sci. 1999, 20: 49-54.PubMed
94.
Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH: Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol. 2002, 59 (4): 527-529.PubMed
95.
Gallus GN, Dotti MT, Federico A: Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci. 2006, 27 (2): 143-149.PubMed
96.
97.
Berginer VM, Foster NL, Sadowsky M, Townsend JA, Siegel GJ, Salen G: Psychiatric disorders in patients with cerebrotendinous xanthomatosis. Am J Psychiatry. 1988, 145 (3): 354-357.PubMed
98.
Barkhof F, Verrips A, Wesseling P, van Der Knaap MS, van Engelen BG, Gabreels FJ, Keyser A, Wevers RA, Valk J: Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology. 2000, 217 (3): 869-876.PubMed
99.
Philippart M, Van Bogaert L: Cholestanolosis (cerebrotendinous xanthomatosis). A follow-up study on the original family. Arch Neurol. 1969, 21 (6): 603-610.PubMed
100.
Shapiro S: Depression in a patient with dementia secondary to cerebrotendinous xanthomatosis. J Nerv Ment Dis. 1983, 171 (9): 568-571.PubMed
101.
Burnstein M, Buckwalter KA, Martel W, McClatchey KD, Quint D: Case report 427: Cerebrotendinous xanthomatosis. Skelet Radiol. 1987, 16 (4): 346-349.
102.
Laurent A, Dairou F, Luc G, Truffert J, Lapresle J, de Gennes JL: Van Bogaert’s cerebrotendinous xanthomatosis. A study of 3 cases. Ann Med Interne. 1988, 139 (6): 395-402.
103.
Wevers RA, Cruysberg JR, Van Heijst AF, Janssen-Zijlstra FS, Renier WO, Van Engelen BG, Tolboom JJ: Paediatric cerebrotendinous xanthomatosis. J Inherit Metab Dis. 1992, 15 (3): 374-376.PubMed
104.
Soffer D, Benharroch D, Berginer V: The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol. 1995, 90 (2): 213-220.PubMed
105.
Verrips A, Steenbergen-Spanjers GC, Luyten JA, van den Heuvel LP, Keyser A, Gabreels FJ, Wevers RA: Two new mutations in the sterol 27-hydroxylase gene in two families lead to cerebrotendinous xanthomatosis. Hum Genet. 1996, 98 (6): 735-737.PubMed
106.
Sperhake JP, Matschke J, Orth U, Gal A, Puschel K: Sudden death due to cerebrotendinous xanthomatosis confirmed by mutation analysis. Int J Legal Med. 2000, 113 (2): 110-113.PubMed
107.
Dotti MT, Rufa A, Federico A: Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings. J Inherit Metab Dis. 2001, 24 (7): 696-706.PubMed
108.
Lee Y, Lin PY, Chiu NM, Chang WN, Wen JK: Cerebrotendinous xanthomatosis with psychiatric disorders: report of three siblings and literature review. Chang Gung Med J. 2002, 25 (5): 334-340.PubMed
109.
Guyant-Marechal L, Verrips A, Girard C, Wevers RA, Zijlstra F, Sistermans E, Vera P, Campion D, Hannequin D: Unusual cerebrotendinous xanthomatosis with fronto-temporal dementia phenotype. Am J Med Genet A. 2005, 139A (2): 114-117.PubMed
110.
Price Evans DA, Salah KA, Mobrad MA, Mitchell WD, Olin M, Eggertsen G: Cerebrotendinous xanthomatosis in a Saudi Arabian family-genotyping and long-term follow-up. Saudi Med J. 2007, 28 (7): 1113-1118.PubMed
111.
Gonzalez-Cuyar LF, Hunter B, Harris PL, Perry G, Smith MA, Castellani RJ: Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Rep. 2007, 12 (3): 119-124.PubMed
112.
Bonnot O, Fraidakis MJ, Lucanto R, Chauvin D, Kelley N, Plaza M, Dubourg O, Lyon-Caen O, Sedel F, Cohen D: Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic Acid. CNS Spectr. 2010, 15 (4): 231-236.PubMed
113.
Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, Pineda M, Sedel F, Topcu M, Vanier MT, Widner H, Wijburg FA, Patterson MC, Group N-CGW: Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab. 2009, 98 (1–2): 152-165.PubMed
114.
115.
Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, on behalf of the NPCGWG: Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. Mol Genet Metab. 2012, 106 (3): 330-344.PubMed
116.
Vanier MT: Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem Res. 1999, 24 (4): 481-489.PubMed
117.
Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, Sedel F: The adult form of Niemann-Pick disease type C. Brain. 2007, 130 (Pt 1): 120-133.PubMed
118.
Trendelenburg G, Vanier MT, Maza S, Millat G, Bohner G, Munz DL, Zschenderlein R: Niemann-Pick type C disease in a 68-year-old patient. J Neurol Neurosurg Psychiatry. 2006, 77 (8): 997-998.PubMedPubMedCentral
119.
Wraith JE, Guffon N, Rohrbach M, Hwu WL, Korenke GC, Bembi B, Luzy C, Giorgino R, Sedel F: Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol Genet Metab. 2009, 98 (3): 250-254.PubMed
120.
Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, Gale SE, Olzeski D, Sidhu R, Dietzen DJ, Fu R, Wassif CA, Yanjanin NM, Marso SP, House J, Vite C, Schaffer JE, Ory DS: Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med. 2010, 2 (56): 56ra81-PubMedPubMedCentral
121.
Patterson MC, Platt F: Therapy of Niemann-Pick disease, type C. Biochim Biophys Acta. 2004, 1685 (1–3): 77-82.PubMed
122.
Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007, 6 (9): 765-772.PubMed
123.
Wraith JE, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, Giorgino R, Patterson MC: Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010, 99 (4): 351-357.PubMed
124.
Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, Giorgino R, Wraith JE: Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol. 2010, 25 (3): 300-305.PubMed
125.
Shulman LM, Lang AE, Jankovic J, David NJ, Weiner WJ: Case 1, 1995: psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. Mov Disord. 1995, 10 (3): 257-262.PubMed
126.
Campo JV, Stowe R, Slomka G, Byler D, Gracious B: Psychosis as a presentation of physical disease in adolescence: a case of Niemann-Pick disease, type C. Dev Med Child Neurol. 1998, 40 (2): 126-129.PubMed
127.
Turpin JC, Baumann N: [Presenting psychiatric and cognitive disorders in adult neurolipidoses]. Rev Neurol. 2003, 159 (6–7 Pt 1): 637-647.PubMed
128.
Josephs KA, Van Gerpen MW, Van Gerpen JA: Adult onset Niemann-Pick disease type C presenting with psychosis. J Neurol Neurosurg Psychiatry. 2003, 74 (4): 528-529.PubMedPubMedCentral
129.
Tyvaert L, Stojkovic T, Cuisset JM, Vanier MT, Turpin JC, De Seze J, Vermersch P: [Presentation of Niemann-Pick type C disease with psychiatric disturbance in an adult]. Rev Neurol. 2005, 161 (3): 318-322.PubMed
130.
Walterfang M, Fietz M, Fahey M, Sullivan D, Leane P, Lubman DI, Velakoulis D: The neuropsychiatry of Niemann-Pick type C disease in adulthood. J Neuropsychiatry Clin Neurosci. 2006, 18 (2): 158-170.PubMed
131.
Walterfang M, Fietz M, Abel L, Bowman E, Mocellin R, Velakoulis D: Gender dimorphism in siblings with schizophrenia-like psychosis due to Niemann-Pick disease type C. J Inherit Metab Dis. 2009, 221-226. Sup1
132.
Sandu S, Jackowski-Dohrmann S, Ladner A, Haberhausen M, Bachmann C: Niemann-Pick disease type C1 presenting with psychosis in an adolescent male. Eur Child Adolesc Psychiatry. 2009, 18 (9): 583-585.PubMed
133.
Walterfang M, Kornberg A, Adams S, Fietz M, Velakoulis D: Post-ictal psychosis in adolescent Niemann-Pick disease type C. J Inherit Metab Dis. 2010, 13 (Sup3): 63-65.
134.
Klunemann HH, Santosh PJ, Sedel F: Treatable metabolic psychosis that go undetecd: What Niemann Pick type C can teach us. Int J Psychiatry Clin Pract. 2012, 16 (3): 1-8.
135.
van de Vlasakker CJ, Gabreels FJ, Wijburg HC, Wevers RA: Clinical features of Niemann-Pick disease type C. An example of the delayed onset, slowly progressive phenotype and an overview of recent literature. Clin Neurol Neurosurg. 1994, 96 (2): 119-123.PubMed
136.
Klarner B, Klunemann HH, Lurding R, Aslanidis C, Rupprecht R: Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations. J Inherit Metab Dis. 2007, 30 (1): 60-67.PubMed
137.
Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Cote TR: Therapies for inborn errors of metabolism: what has the orphan drug act delivered?. Pediatrics. 2010, 126 (1): 101-106.PubMed
138.
Andreasen NC: The evolving concept of schizophrenia: from Kraepelin to the present and future. Schiz Res. 1997, 28 (2–3): 105-109.
139.
van Os J, Driessen G, Gunther N, Delespaul P: Neighbourhood variation in incidence of schizophrenia. Evidence for person-environment interaction. Br J Psychiatry. 2000, 176: 243-258.PubMed
140.
141.
Weinberger DR: From neuropathology to neurodevelopment. Lancet. 1995, 346 (8974): 552-557.PubMed
142.
Van Gorkom HJ, Pulles MP, Wessels JS: Light-induced changes of absorbance and electron spin resonance in small photosystem II particles. Biochim Biophys Acta. 1975, 408 (3): 331-339.PubMed
143.
van Os J, Kapur S: Schizophrenia. Lancet. 2009, 374 (9690): 635-645.PubMed
144.
Cutting J: The phenomenology of acute organic psychosis. Comparison with acute schizophrenia. Br J Psychiatry. 1987, 151: 324-332.PubMed
145.
Horiguchi J, Miyaoka T, Shinno H: Pathogenesis and symptomatology of hallucinations (delusions) of organic brain disorder and schizophrenia. Psychogeriatrics. 2009, 9 (2): 73-76.PubMed
146.
Barak Y, Aizenberg D, Mirecki I, Mazeh D, Achiron A: Very late-onset schizophrenia-like psychosis: clinical and imaging characteristics in comparison with elderly patients with schizophrenia. J Nerv Ment Dis. 2002, 190 (11): 733-736.PubMed
147.
Teeple RC, Caplan JP, Stern TA: Visual hallucinations: differential diagnosis and treatment. Prim Care Companion J Clin Psychiatry. 2009, 11 (1): 26-32.PubMedPubMedCentral
148.
Cornic F, Consoli A, Tanguy ML, Bonnot O, Perisse D, Tordjman S, Laurent C, Cohen D: Association of adolescent catatonia with increased mortality and morbidity: evidence from a prospective follow-up study. Schizophr Res. 2009, 113 (2–3): 233-240.PubMed
149.
Remschmidt H, Theisen F: Early-onset schizophrenia. Neuropsychobiology. 2012, 66 (1): 63-69.PubMed
150.
Walterfang M, Bonnot O, Mocellin R, Velakoulis D: The neuropsychiatry of inborn errors of metabolism. J Inherit Metab Dis. 2013, 36 (4): 687-702.PubMed
151.
McEvoy JP: The costs of schizophrenia. J Clin Psychiatry. 2007, 68 (Suppl 14): 4-7.PubMed
Metadata
Title
Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review
Authors
Olivier Bonnot
Hans Hermann Klünemann
Frederic Sedel
Sylvie Tordjman
David Cohen
Mark Walterfang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2014
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-9-65

Other articles of this Issue 1/2014

Orphanet Journal of Rare Diseases 1/2014 Go to the issue

Research

Estimating the budget impact of orphan drugs in Sweden and France 2013–2020

Research

Assessing the role of multiple pregnancies in the association between tetralogy of Fallot and assisted reproductive techniques: a path-analysis approach

Research

Atypical multisensory integration in Niemann-Pick type C disease – towards potential biomarkers

Letter to the Editor

Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen

Letter to the Editor

Expression of the SERPING1 gene is not regulated by promoter hypermethylation in peripheral blood mononuclear cells from patients with hereditary angioedema due to C1-inhibitor deficiency

Research

Expanding the phenotypic spectrum of ARID1B-mediated disorders and identification of altered cell-cycle dynamics due to ARID1B haploinsufficiency